Effectiveness of Combined Tobacco Treatment in Hospitalized Subjects

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorNational Institute of Respiratory Diseases, Mexico

About this trial

In the 20th century, tobacco caused the death of 100 million people worldwide and it is estimated that it will be responsible for 1 billion deaths in the 21st century. Currently 8 million people die each year from smoking, 7 million are associated with active smoking, thus being the main risk factor for loss of disability-adjusted life years for men and the ninth most important risk factor for women. In previous studies it has been reported that approximately 21% (14%-30%) of subjects who have required hospitalization are active smokers, being higher in men than in women (28% vs 14%). The initiation of treatment for smoking cessation in this group of subjects has shown an effectiveness rate of up to 65% to maintain abstinence 6 to 12 months after discharge. The effectiveness has been analyzed in scenarios with only brief advice, in some others with the use of medications such as varenicline, bupropion and nicotine replacement therapy, however, the interventions have not been standardized for adequate analysis, which could contribute to the different results.

Eligibility criteria

Qualifiers

None

Disqualifiers

Subjects who have had pharmacological treatment to stop smoking in the last month

Subjects with contraindications for medications.

Trial design

Treatments tested in this trial

  • Bupropion
  • Nicotine replacement therapy (Nicotine patches)

Treatment groups

134 Participants
are divided into 2 treatment groups